SCHEMBL729520

SCHEMBL729520

O=C(O)CCCCCCCCCCC(=O)OCCO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 4/20 0.56
FFAR1 O14842 2/20 0.56
FFAR4 Q5NUL3 2/20 0.56
TSHR P16473 5/20 0.52
LMNA P02545 2/20 0.52
NFKB1 P19838 1/20 0.52
PMP22 Q01453 1/20 0.52
DGKA P23743 1/20 0.52
ALDH1A1 P00352 3/20 0.48
CAMK2A Q9UQM7 1/20 0.48
PAM P19021 2/20 0.47
MGLL Q99685 1/20 0.45
PPARG P37231 4/20 0.43
PPARD Q03181 4/20 0.43
PPARA Q07869 4/20 0.43
HDAC11 Q96DB2 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
SLC22A8 Q8TCC7 1/20 0.43
TLR2 O60603 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28304556 1.00 GPR84 (0.56) GPR84FFAR1FFAR4TSHRLMNA
SCHEMBL176409 1.00 GPR84 (0.56) GPR84FFAR1FFAR4TSHRLMNA
SCHEMBL4159638 1.00 GPR84 (0.56) GPR84FFAR1FFAR4TSHRLMNA
SCHEMBL28287969 1.00 GPR84 (0.56) GPR84FFAR1FFAR4TSHRLMNA
Ammonia Solution, Strong SCHEMBL27527875 0.98 GPR84 (0.54) GPR84FFAR1FFAR4TSHRLMNA
Ammonia Solution, Strong SCHEMBL27470632 0.98 GPR84 (0.54) GPR84FFAR1FFAR4TSHRLMNA
Water SCHEMBL28518811 0.98 GPR84 (0.54) GPR84FFAR1FFAR4TSHRLMNA
Ammonia Solution, Strong SCHEMBL27593614 0.98 GPR84 (0.54) GPR84FFAR1FFAR4TSHRLMNA
SCHEMBL26442 0.98 GPR84 (0.52) GPR84FFAR1FFAR4TSHRLMNA
Ammonia Solution, Strong SCHEMBL7134656 0.96 GPR84 (0.50) GPR84FFAR1FFAR4TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3193834-B1 PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS VIRUN INC (US) 2020-04-01 EP claimed
US-10085951-B2 Curcuminoid formulations and related methods of treatment DESIGNS FOR HEALTH, INC. (US) 2018-10-02 US claimed
US-10016363-B2 Pre-spray emulsions and powders containing non-polar compounds VIRUN, INC. (US) 2018-07-10 US claimed
EP-3193834-A1 PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2017-07-26 EP claimed
US-20160227832-A1 FORMULATIONS OF WATER-SOLUBLE DERIVATIVES OF VITAMIN E AND COMPOSITIONS CONTAINING SAME VIRUN, INC. 2016-08-11 US claimed
US-20160166516-A1 NOVEL CURCUMINOID FORMULATIONS AND RELATED METHODS OF TREATMENT TCW PT MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT 2016-06-16 US claimed
US-9351517-B2 Formulations of water-soluble derivatives of vitamin E and compositions containing same VIRUN, INC. (US) 2016-05-31 US claimed
WO-2016044813-A9 PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2016-05-26 WO claimed
US-20160081927-A1 PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. 2016-03-24 US claimed
US-20160081975-A1 SOFT GEL COMPOSITIONS AND PRE-GEL CONCENTRATES VIRUN, INC. 2016-03-24 US claimed
WO-2016044813-A1 PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS VIRUN, INC. (US) 2016-03-24 WO claimed
WO-2016044805-A1 SOFT GEL COMPOSITIONS AND PRE-GEL CONCENTRATES VIRUN, INC. (US) 2016-03-24 WO claimed
EP-2983525-A1 FORMULATIONS OF WATER-SOLUBLE DERIVATIVES OF VITAMIN E AND COMPOSITIONS CONTAINING SAME VIRUN, INC. (US) 2016-02-17 EP claimed
CN-105228470-A Vitamin E soluble derivative preparation and comprise its composition VIRUN INC 2016-01-06 CN claimed
WO-2014151109-A1 FORMULATIONS OF WATER-SOLUBLE DERIVATIVES OF VITAMIN E AND COMPOSITIONS CONTAINING SAME VIRUN, INC. (US) 2014-09-25 WO claimed
US-20140271593-A1 FORMULATIONS OF WATER-SOLUBLE DERIVATIVES OF VITAMIN E AND COMPOSITIONS CONTAINING SAME VIRUN, INC. 2014-09-18 US claimed
US-6140514-A Process for the preparation of macrocyclic esters or lactones HUELS AKTIENGESELLSCHAFT (DE) 2000-10-31 US claimed
CN-114524923-B Biodegradable polyester based on dodecanedioic acid and ethylene glycol, and preparation method and application thereof 天津工业大学 2024-02-27 CN disclosed
US-6140514-A Process for the preparation of macrocyclic esters or lactones HUELS AKTIENGESELLSCHAFT (DE) 2000-10-31 US disclosed
US-6121466-A HEATING DICARBOXYLIC ACID (BIS)GLYCOL ESTERS AND GLYCOL; CATALYSIS, DISTILLATION HUELS AKTIENGESELLSCHAFT (DE) 2000-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166516-A1 NOVEL CURCUMINOID FORMULATIONS AND RELATED METHODS OF TREATMENT FABP2, SLC46A1, MTHFD2 GPR84 1167/4885FFAR1 716/4885FFAR4 610/4885
US-10085951-B2 Curcuminoid formulations and related methods of treatment MTHFD2, SLC46A1, SLC19A1 GPR84 1717/4885FFAR1 964/4885FFAR4 818/4885
US-10016363-B2 Pre-spray emulsions and powders containing non-polar compounds ELOVL6, ELOVL3, NDUFA6 GPR84 3398/4885FFAR1 562/4885FFAR4 754/4885
US-20140271593-A1 FORMULATIONS OF WATER-SOLUBLE DERIVATIVES OF VITAMIN E AND COMPOSITIONS CONTAINING SAME TTPA, PTGES, HPGDS GPR84 1227/4885FFAR1 1539/4885FFAR4 1752/4885
US-20160081975-A1 SOFT GEL COMPOSITIONS AND PRE-GEL CONCENTRATES ELOVL6, ELOVL3, GSTO1 GPR84 3855/4885FFAR1 1420/4885FFAR4 1633/4885
US-20160081927-A1 PRE-SPRAY EMULSIONS AND POWDERS CONTAINING NON-POLAR COMPOUNDS ELOVL6, ELOVL3, NDUFA6 GPR84 3398/4885FFAR1 562/4885FFAR4 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.